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Edited by Angel NebredaAbstract In this study, we showed that curcumin treatment re-
sulted in activation of Chk1-mediated G2 checkpoint, which was
associated with the induction of G2/M arrest and the resistance
of cancer cells to curcumin-induced apoptosis. Further investiga-
tion revealed that inhibition of Chk1 signiﬁcantly abrogated G2/
M arrest and sensitized curcumin-resistant cells to apoptosis via
upregulation of Bad and in turn the loss of mitochondrial mem-
brane potential. These results indicate that Chk1-mediated G2/
M arrest may serve as a mechanism for curcumin resistance
and Chk1 represents a potential target for the reversal of this
resistance. Our ﬁndings should be helpful for clinical application
of curcumin.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Curcumin, a naturally occurring yellow pigment isolated
from turmeric, is a well known antioxidant. Increasing evi-
dences also suggest curcumin as a DNA-damaging agent [1–
4]. Curcumin is able to induce apoptosis in various cancer cell
lines [5] and to suppress cancer formation [6–8], angiogenesis
[9] and metastasis [10] in mouse models. Both phase I and II
clinical trials show that curcumin is well tolerated and is eﬀec-
tive for cancer patients [11,12], suggesting curcumin as a po-
tential drug in cancer prevention and therapy.
Every anticancer drug encounters the problem of drug resis-
tance, which is responsible for limited eﬀect of chemotherapy
and high cancer mortality. Therefore, understanding the molec-
ular mechanisms of drug resistance and developing the agentsAbbreviations: siRNA, short-interfering RNA; RNAi, RNA interfer-
ence; RT-PCR, reverse transcription-polymerase chain reaction;
hPBGD, human porphobilinogen deaminase; FoxM1, forkhead box
M1; PI, propidium iodide; p-Chk1, phosphorylated-Ser317-Chk1; p-
Chk2, phosphorylated-Thr68-Chk2; p-p38, phosphorylated-Thr180/
Tyr182-p38; p-Cdk1, phosphorylated-Tyr15-Cdk1
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of cancer patients. Most anticancer drugs exert their function
via induction of apoptosis. However, these drugs may also acti-
vate cell cycle checkpoints, which results in cell cycle arrest and
thus protects cells from apoptosis [13,14]. Because malignant
cells often have defects in G1 checkpoint, anticancer treatment
usually activates G2 checkpoint in tumor cells. Hence, G2
checkpoint in fact represents a survival mechanism for cancer
cells to escape apoptosis induced by anticancer therapy [15].
To date, comprehensive studies have been conducted to
characterize the anticancer eﬀect of curcumin, but little is
known about curcumin resistance. It has been found that cur-
cumin can induce cell cycle arrest at the G2/M phase [16–20],
but whether G2/M arrest is associated with the resistance of
cancer cells to curcumin-induced cytotoxicity is still unknown.
In this study, we aimed to investigate the role of G2/M arrest
in curcumin resistance and to identify the potential targets for
reversing this resistance. Our ﬁndings should be helpful for the
clinical application of curcumin.2. Materials and methods
2.1. Reagents
Rabbit polyclonal antibodies against phospho-Ser317 of Chk1,
Chk1, phospho-Thr68 of Chk2, Chk2, phospho-Tyr15 of Cdk1, Bcl-
2 (Cell Signaling Technology, Beverly, MA) and Mcl-1 (Santa Cruz
Biotechnology, Santa Cruz, CA); mouse monoclonal antibodies
against phospho-Thr180/Tyr182 of p38, p38a, Cdk1, Bad (BD Pharm-
ingen International, San Diego, CA), b-actin and Bcl-XL (Santa Cruz);
lipofectamine–RNA interference (RNAi) MAX, Trizol, and goat-anti-
mouse Alexa 488 (Invitrogen, Carlsbad, CA); p38 inhibitor SB203580
(Promega, Madison, WI). Curcumin (Sigma–Aldrich, St. Louis, MO)
was dissolved in DMSO in a concentration of 25 mM and stored at
20 C in aliquot.
2.2. Apoptosis assay
The hepatoma cell lines, including Huh7, Hep3B, HepG2, SK-Hep-1
and QGY-7703, and colon cancer cell line HCT-116(p53/) were
grown in DMEM supplemented with 10% FBS and 2 mM/l L-gluta-
mine. Apoptosis was evaluated by staining with 4 0-6 0-diamidino-2-
phenylindole (Sigma). Cells with nuclear fragmentation or DNA con-
densation were counted as apoptotic cells. At least 500 cells were
counted for each sample.
2.3. Analysis for cell cycle distribution
Cells were resuspended in Krishans reagent (0.05 mg/ml propidium
iodide (PI), 0.1% Na citrate, 0.02 mg/ml ribonuclease A, 0.3% NP-40),
incubated at 37 C for 30 min and applied to ﬂuorescence-activated cell
sorting (Becton Dickinson FACS Vantage SE, San Jose, CA).blished by Elsevier B.V. All rights reserved.
2690 W.-Z. Wang et al. / FEBS Letters 582 (2008) 2689–26952.4. Western blotting
Proteins were separated on 8–15% SDS–polyacrylamide gels, elec-
trophoretically transferred to nitrocellulose membranes, and detected
by speciﬁc antibodies and ECL kit (Pierce, Rockford, IL). The quan-
tiﬁcation of protein was performed by densitometry analysis using
Glyko Bandscan software (Glyko Inc., USA).
2.5. Transfection of short-interfering RNA (siRNA)
The siRNA sequences targeted human Chk1 (GeneBank accession
no. NM_001274), Chk2 (GeneBank accession no. NM_007194) and
Bad (GeneBank accession no. NM_004322) transcripts were desig-
nated as si-Chk1, si-Chk2 and si-Bad, respectively. The target se-
quences selected for RNAi were: 5 0-AAG AAG CAG TCG CAG
TGA AGA TTG TAG for Chk1 gene, 5 0-AAG AAC CTG AGG
ACC AAG AAC CTG AGG for Chk2 gene and 5 0-AGT GAC
GAG TTT GTG GAC TCC TTT A for Bad gene. A scrambled se-
quence (sense – 5 0-CGU ACU GUC GAC ACU GAA ACG GAdC
dA; antisense – 5 0-UAU CCG UUU CAG UGU CGA CAG UAC
GdTdG) named si-NC, which was non-homologous to any human
DNA sequence, was used as negative control. Cells were transfected
with siRNA duplex using lipofectamine–RNAi MAX according to
the manufacturers instructions.
2.6. Reverse transcription-polymerase chain reaction (RT-PCR)
The speciﬁc primers used to amplify the Chk1, Chk2, Bad and the
house keeping gene human porphobilinogen deaminase (hPBGD) were
as follows: Chk1, 5 0-CCT TTG TGG AAG ACT GGG ACT and 5 0-
GAG GTT ATC CCT TTC ATC CAA C; Chk2, 5 0-TCG TGA
TGT CTC GGG AGT CG and 5 0-GAG TTT GGC ATC GTG
CTG GT; Bad, 5 0-GCT CCG GCA AGC ATC ATC and 5 0-CCA
TCC CTT CGT CGT CCT C; hPBGD, 5 0-TCT GGT AAC GGC
AAT GCG G and 5 0-GCA GAT GGC TCC GAT GGT G. hPBGD
was ampliﬁed together with Chk1 or Chk2 or Bad in the same reaction,
serving as an internal control.
2.7. Immunoﬂouresence staining
Cells were ﬁxed with 4% paraformaldehyde, permeabilized and
blocked in 1 · PBS containing 0.3% Triton X-100 and 5% normal goat
serum, followed by incubation with monoclonal antibody against Bad
(1:100) and then with goat-anti-mouse Alexa-488 conjugated second-
ary antibody (1:200). Nuclei were visualized by PI staining.
2.8. Analysis of mitochondrial membrane potential (DWm)
Loss of DWm was determined using 5,5 0,6,6 0-tetrachloro- 1,1 0,3,3 0-
tetraethylbenzimidazolyl-carbocyanine iodide (JC-1, Merck Calbio-
chem, Germany) [21]. Cells were washed three times with 1 · PBS
and then incubated at 37 C for 20 min with DMEM supplemented
with 10% FBS and 10 lg/ml JC-1.
2.9. Statistical analysis
Values represent the mean ± S.D. from at least three independent
experiments. Diﬀerences between the experimental groups were ana-
lyzed using Students t-test. A value of P < 0.05 was considered statis-
tically signiﬁcant.3. Results
3.1. Resistance to curcumin-induced apoptosis is closely related
to G2/M arrest
To investigate whether G2/M arrest is associated with the
resistance of cancer cells to curcumin-induced cytotoxicity,
we ﬁrst analyzed the apoptosis rate and the cell cycle distribu-
tion in hepatoma cell lines (Huh7, Hep3B, HepG2, SK-Hep-1
and QGY-7703) treated with 25 lM of curcumin for 24 h.
Interestingly, the rate of apoptosis was inversely related to
the percentage of cells at the G2/M phase after curcumin treat-
ment (Fig. 1A–D and data not shown). Thereafter, the cell
lines that are most sensitive (Huh7) and most resistant
(Hep3B) to curcumin-induced apoptosis were chosen for fur-ther study in greater detail. We found that curcumin-induced
apoptosis in Huh7 cells in a dose- and time-dependent manner
(Fig. 1A), while Hep3B cells were very resistant to curcumin-
induced apoptosis even at a high dose of 50 lM and an ex-
tended treatment time of 48 h (Fig. 1B). Furthermore, curcu-
min exposure did not signiﬁcantly change the cell cycle
distribution in Huh7 cells (Fig. 1C), but resulted in dramatic
accumulation of Hep3B cells at the G2/M phase (Fig. 1D).
These observations suggest that G2/M arrest may be associ-
ated with the resistance of Hep3B cells to curcumin-induced
apoptosis. Therefore, we next examined whether G2 check-
point was activated in curcumin-treated Hep3B cells.
3.2. Curcumin treatment results in activation of G2 checkpoint in
Hep3B cells
Both DNA damage and environmental insult may activate
the G2 checkpoint and result in G2/M arrest. It has been
shown that DNA damage sensor Chk1/Chk2 plays a role in
G2 checkpoint via ATM/ATR pathway [22], while the stress
sensor p38 acts through ATM/ATR-independent pathway
[23]. Activation of ATM/ATR-dependent and -independent
pathways causes respective phosphorylation of Chk1-Ser317/
Chk2-Thr68 and p38-Thr180/Tyr182, which consequently pre-
vents the dephosphorylation of Thr14/Tyr15 in the Cdk1 ki-
nase and in turn leads to G2/M arrest. To investigate
whether G2 checkpoint is activated upon curcumin treatment,
the kinetic changes of phosphorylated-Ser317-Chk1 (p-Chk1),
phosphorylated-Thr68-Chk2 (p-Chk2), phosphorylated-
Thr180/Tyr182-p38 (p-p38) and phosphorylated-Tyr15-Cdk1
(p-Cdk1) were analyzed. Considering that the proteins we ana-
lyzed might display cyclic expression during cell cycle, cells
treated with DMSO (ﬁnal concentration 0.1%, the vehicle of
curcumin) were collected at each time point as those exposed
to 25 lM curcumin and were used as negative control (Fig.
1E and F). Compared to DMSO-treated Hep3B cells, the p-
Cdk1 level signiﬁcantly increased in curcumin-treated cells,
while total amount of Cdk1 remained the same between
DMSO- and curcumin-exposed cells at every time point (Fig.
1F). The increased phosphorylation became evident at 12 h
post-treatment, which is in accordance with the onset of G2/
M arrest at this time point. Furthermore, the levels of p-
Chk1 and p-p38 increased simultaneously as that of p-Cdk1
(Fig. 1F). However, no alteration in the amount of p-Chk2
was found (data not shown). As control, the total and p-
Chk1, p-Chk2, p-p38 and p-Cdk1 proteins in DMSO- or cur-
cumin-treated Huh7 cells were also analyzed. We found an
dramatic increase of p-p38 at 12 h but no obvious change in
the level of p-Chk1, p-Chk2 and p-Cdk1 in curcumin-exposed
Huh7 cells compared with DMSO-treated ones (Fig. 1E).
These results suggest that curcumin treatment results in G2
checkpoint activation in Hep3B cells via Chk1- or p38-Cdk1-
mediated pathway, which may be associated with G2/M arrest
and with the resistance of Hep3B to curcumin-induced apopto-
sis. Hep3B cells were thus employed to validate this contention
in the following study.
3.3. Abrogation of Chk1-mediated G2/M arrest sensitizes
curcumin-resistant Hep3B cells to apoptosis
To investigate whether Chk1 or p38 mediated the G2/M ar-
rest in our cell model, we used RNAi technique to silence the
expression of Chk1 and Chk2 genes (Fig. 2A) and found that
knockdown of Chk1 eliminated the accumulation of p-Cdk1
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Fig. 1. Eﬀect of curcumin on apoptosis rate, cell cycle distribution and expression of G2 checkpoint-related proteins. (A and B) The rate of
apoptosis. Huh7 (A) or Hep3B (B) cells were treated with either DMSO for 48 h (vehicle control, indicated as D) or 25 or 50 lM curcumin for
indicated times. Images presented over panels A and B show apoptotic nuclei (indicated by arrows) for Huh7 and Hep3B cells, respectively. (C and
D) The cell cycle distribution. Huh7 (C) or Hep3B (D) cells were treated with DMSO (indicated as D) for 48 h or 25 lM curcumin for indicated
times. (E and F) Expression of G2 checkpoint-related proteins. Huh7 (E) or Hep3B (F) cells were treated with DMSO (indicated as D) or 25 lM
curcumin (indicated as C) for 12, 20 and 24 h. b-Actin was used as control for protein loading. The value under each band in (E) and (F) indicates the
relative expression level of protein. The intensity for each band was densitometrically quantiﬁed and then normalized by the intensity of b-actin in
each lane. The normalized intensity in the ﬁrst lane was set as relative expression level of 1.
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Meanwhile, Chk1 silencing dramatically attenuated curcumin-
induced G2/M arrest (Fig. 2C) and conferred signiﬁcant poten-tiation of apoptosis (Fig. 2D) in Hep3B cells. However, Chk2
knockdown failed to aﬀect the level of p-Cdk1, to
abrogate curcumin-induced G2/M arrest and to sensitize
2692 W.-Z. Wang et al. / FEBS Letters 582 (2008) 2689–2695Hep3B cells to apoptosis (Fig. 2B–D), which was consistent
with our above observation that the level of p-Chk2 was not
changed after curcumin treatment. Surprisingly, neither could
double knockdown of the Chk1/Chk2 aﬀect the rate of G2/M
arrest and apoptosis in curcumin-treated cells, even the level of
p-Cdk1 was obviously decreased (Fig. 2B–D).si-
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-actinβNext the role of p38 was characterized. Hep3B cells were ex-
posed to 20 lM of p38 inhibitor (SB203580) for 2 h prior to
curcumin treatment and were incubated with both SB203580
(20 lM) and curcumin (25 lM) for another 6, 12, 24 or 48 h.
However, inhibition of p38 displayed no inﬂuence on the
Cdk1 phosphorylation, G2/M arrest and apoptosis of curcu-
min-exposed cells (data not shown). These ﬁndings suggest
that Chk1- but not p38-Cdk1-mediated G2/M arrest confers
Hep3B cells with the resistance to curcumin-induced apoptosis
and abrogation of this arrest sensitizes Hep3B to apoptosis.
3.4. Abrogation of G2/M arrest may sensitize curcumin-resistant
Hep3B cells to apoptosis via upregulation of Bad and loss of
DWm
To investigate which apoptosis regulating pathways have
been triggered when Chk1 is silenced, we ﬁrst examined the
mitochondrial pathway by determining the DWm with JC-1, a
ﬂuorescent dye that detects normal mitochondria as red color
and depolarized mitochondria as yellow/green. Compared with
the si-NC-transfected Hep3B cells, the si-Chk1-transfected
Hep3B displayed an obvious loss of DWm after curcumin treat-
ment (Fig. 3A).
It is well known that Bcl-2 family members play crucial roles
in regulating the permealization of mitochondrial membrane
[24], we thus assessed the relative expression levels of these pro-
teins by Western blotting and immunoﬂuorescent staining. The
results showed that si-Chk1- but not si-NC-transfected cells
presented an increase in the Bad protein level after curcumin
exposure (Fig. 3B and C). However, the expression of other
Bcl-2 family members including Bcl-2, Bcl-XL and Mcl-1 re-
mained unchanged (Fig. 3B). To further investigate whether
Bad is the critical molecule that triggered curcumin-induced
apoptosis in Chk1-depleted-Hep3B cells, we employed RNAi
technique to silence the expression of Bad gene and showed
that Bad knockdown dramatically blocked the eﬀect of Chk1
depletion in curcumin-treated Hep3B cells, in a dose-depen-
dent manner (Fig. 4A). This observation was further validated
on HCT-116(p53/), a colon cancer cell line with targeted
deletion of p53. We found that HCT-116(p53/) cells, which
displayed dramatic accumulation at the G2/M phase (from
18% to 70%) after curcumin treatment, were resistant to curcu-
min-induced apoptosis (Fig. 4B). Moreover, Chk1 silencing
signiﬁcantly sensitized curcumin-treated HCT-116(p53/)
cells to apoptosis, while such Chk1-depletion-promoted apop-
tosis was attenuated by Bad knockdown (Fig. 4B). TheseFig. 2. Eﬀect of Chk1 and Chk2 knockdown on curcumin-treated
Hep3B cells. (A) The mRNA and protein levels of Chk1 and Chk2.
Cells were analyzed 48 h after transfection with 50 nM of indicated
siRNA by RT-PCR and Western blotting. The hPBGD and b-actin
were served as internal controls for mRNA and protein levels,
respectively. CON, Hep3B cells without any treatment; si-NC, a
scrambled siRNA used as a negative control; si-Chk1, siRNA targeted
Chk1; si-Chk2, siRNA targeted Chk2. (B) The level of Cdk1
phosphorylation. The value under each band in (A) and (B) indicates
the relative expression level of protein. For details, see Fig. 1 legend.
(C) The distribution of cell cycle. (D) The rate of apoptosis. Cells were
transfected with 50 nM of indicated siRNA, followed by treatment
with DMSO (as vehicle control) or with 25 lM curcumin for 24 h (for
the analysis of Cdk1 phosphorylation and cell cycle distribution) or
48 h (for apoptosis analysis). The X-axis in panels B–D denoted the
treatments for each sample, which were presented on the top of panel
B. CUR, curcumin. *P < 0.05; **P < 0.01.
b
Fig. 3. Characterization of the signaling pathways triggered to induce apoptosis in curcumin-treated Hep3B cells after Chk1 depletion. (A) Analysis
of mitochondrial membrane potential using JC-1. (B and C) The expression levels of Bcl-2 family members analyzed by Western blotting (B) or
immunoﬂouresence staining (C). Cells were transfected with 50 nM of indicated siRNA for 48 h, followed by treatment with 25 lM curcumin for
another 24 h and then applied to analysis. b-Actin was used as control for protein loading. The value under each band in (B) indicates the relative
expression level of protein. For details, see Fig. 1 legend. CUR, curcumin; si-NC, a scrambled siRNA used as a negative control; si-Chk1, siRNA
targeted Chk1; PI, propidium iodide.
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tant cells to apoptosis via upregulation of Bad and in turn the
loss of DWm.4. Discussion
In the present study, we showed that Chk1-mediated activa-
tion of G2 checkpoint was required for curcumin-induced G2/
M arrest, and Chk1 inhibition signiﬁcantly abrogated this ar-
rest and sensitized curcumin-resistant cells to apoptosis. Previ-
ous studies have also demonstrated that ablation of the G2
checkpoint could potentiate cell death induced by ionizing
radiation [25], DNA-damaging agents [13,14] and non-DNA-damaging agents [26,27], strongly supporting G2 checkpoint
as a potential therapeutic target for the reversal of drug resis-
tance [15]. Undoubtedly, overcoming this resistance will signif-
icantly broaden the application of curcumin in cancer therapy.
In addition, Hep3B cells have been shown to be resistant to
diﬀerent apoptotic inducing factors, such as FAS, TRAIL
and paclitaxel [28–30]. It will be interesting to investigate
whether G2 checkpoint is a target for reversing the resistance
of Hep3B to other apoptosis stimuli.
Abrogation of curcumin-induced G2/M arrest and decreased
phosphorylation of Cdk1 at the Tyr15 site were simultaneously
found in Hep3B cells with single knockdown of Chk1. How-
ever, double knockdown of both Chk1 and Chk2 could not
eliminate the G2/M arrest (Fig. 2C), although decreased accu-
2694 W.-Z. Wang et al. / FEBS Letters 582 (2008) 2689–2695mulation of p-Cdk1 was observed (Fig. 2B, lane 10). One pos-
sible explanation for these observations is that Chk1 silencing
may abrogate G2 checkpoint via Chk2-mediated signaling
pathway. Aside from dephosphorylation at Tyr15, full activa-
tion of Cdk1 also requires binding to cyclin B1. It has been
found that transcriptional activation of cyclin B1 by the fork-
head box M1 (FoxM1) transcription factor is essential for
timely mitotic entry [31], while FoxM1 protein is stabilized
by Chk2 in response to DNA damage [32]. Therefore, we spec-
ulate that simultaneous dephosphorylation at Cdk1-Tyr15
(through Chk1 depletion) and increase in cyclin B1 expression
(via Chk2-FoxM1 signaling pathway) are required for the
checkpoint abrogation and cell cycle progression in our study
model.
Increasing evidence indicates that ectopic expression of anti-
apoptotic proteins such as Hsp70, Bcl-XL or Ku70 confers
cancer cells with resistance to curcumin-induced apoptosis
[33,34]. In addition, human colon cancer cells lacking Bax also
resist curcumin-induced apoptosis [35]. Interestingly, we found
that expression of Bad, the proapoptotic molecule in the Bcl-2
family, increased obviously after release of G2/M arrest (Fig.
3B and C). Moreover, Bad knockdown dramatically attenu-
ated curcumin-induced apoptosis in Chk1 depleted-cells (Fig.
4). These results indicate the existence of crosstalk between
the signaling pathways that control apoptosis and the cell cy-
cle, when curcumin-induced G2/M arrest is released by Chk1
knockdown.
In summary, we characterize the molecular mechanisms
underlying curcumin resistance as well as the reversal of this
resistance. Our data indicate that (1) Chk1-mediated G2/M ar-
rest may serve as a mechanism for the resistance of cancer cells
to curcumin-induced apoptosis; (2) Chk1 represents a potential
target for the reversal of curcumin resistance; (3) Bad is the
critical molecule that triggered apoptosis in curcumin-resistant
cells after Chk1 depletion. These ﬁndings should be helpful for
the clinical application of curcumin.
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